Cannabis Bioscience International Holdings (CBIH) Current Deferred Revenue (2023 - 2025)
Cannabis Bioscience International Holdings' (CBIH) quarterly Current Deferred Revenue came in at $12000.0 in Q3 2025, down 58.1% quarter-over-quarter from $28641.0 in Q2 2023.
Cannabis Bioscience International Holdings (CBIH) Current Deferred Revenue (2023 - 2025) Analysis & Trends
Cannabis Bioscience International Holdings has disclosed Current Deferred Revenue across 2 years of filings, most recently posting $12000.0 for Q3 2025.
- Current Deferred Revenue for Q3 2025 came in at $12000.0, changed N/A year-over-year; the trailing twelve-month figure through Aug 2025 was $12000.0 (changed N/A YoY), and the FY2023 annual result was $28641.0, changed N/A from the prior year.
- Current Deferred Revenue came in at $12000.0 for Q3 2025 at Cannabis Bioscience International Holdings, down from $28641.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $28641.0 in Q2 2023 to a low of $12000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Cannabis Bioscience International Holdings | - | - | 8,160.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2025 | 12,000.00 |
| May 31, 2023 | 28,641.00 |